Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5172212 | 0.81 | GPR119 (0.38) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL23376785 | 0.79 | GPR119 (0.38) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL6172899 | 0.79 | GPR119 (0.38) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL24915163 | 0.79 | GPR119 (0.38) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL14860682 | 0.79 | GPR119 (0.38) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL26536604 | 0.78 | GPR119 (0.37) | GPR119BCHEPOLBHTTATM | |
| SCHEMBL2471937 | 0.78 | GPR119 (0.37) | GPR119GABRG2GABRB3GABRA5BCHE | |
| SCHEMBL5849847 | 0.78 | GPR119 (0.37) | GPR119GABRG2GABRB3GABRA5BCHE | |
| SCHEMBL29102405 | 0.77 | KDM4E (0.35) | MEN1KMT2AMAPT | |
| SCHEMBL4145435 | 0.77 | GPR119 (0.36) | GPR119BCHEPOLBHTTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4514804-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | Viscient Bio, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| CN-119487031-A | Tryptanthrin derivatives and uses thereof | 威森特生物公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023211977-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | VISCIENT BIO, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-116514799-A | Wee1 inhibitor, composition and application thereof | 星希尔生物科技(上海)有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153674-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-04-10 | — | — | US | disclosed |
| CN-101657444-A | Derivatives and analogs of chroman as functionally selective alpha2C adrenoreceptor agonists | SCHERING CORP US | 2010-02-24 | — | — | CN | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| US-20090182007-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| CN-101410389-A | Organic compounds | NOVARTIS AG (CH) | 2009-04-15 | — | — | CN | disclosed |
| EP-2001866-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-7329764-B2 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007117982-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20050038104-A1 | Substitute benzothiophene compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171452-A1 | TRYPTANTHRIN DERIVATIVES AND USES THEREOF | IDO2, IDO1, TPSB2 | GPR119 555/4885GABRG2 3682/4885GABRB3 3502/4885 |
| US-20050038104-A1 | Substitute benzothiophene compounds | TST, SULT1E1, LTC4S | GPR119 1170/4885GABRG2 2616/4885GABRB3 1238/4885 |
| US-20090182007-A1 | ORGANIC COMPOUNDS | REN, CYP17A1, HSD17B1 | GPR119 530/4885GABRG2 4622/4885GABRB3 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.